Regenerative medicine company Orthocell (ASX:OCC) has announced it has been granted Canadian and Japan divisional patents for CelGro.
The company said the patents entitled 'Method for Producing a Collagen Membrane and Uses Thereof' provide additional intellectual property (IP) to protect the platform for soft tissue regeneration and repair applications expiring in June 2033.
Orthocell Managing Director, Paul Anderson, said, “In line with our IP strategy, we are focused on establishing and maintaining protection of our leading manufacturing technologies and treatment processes.
"Securing a divisional patent for CelGro in Canada and Japan is another milestone in strengthening our IP position in global markets. This complements the progression of our products through the registration processes in the US, EU and Australia.”
Orthocell said it has secured 11 patent families covering its portfolio of regenerative medicine products, comprising 108 separate patents and applications, of which 78 are granted.
CelGro is a customisable collagen medical device manufactured by the company at its quality controlled (GMP) facility in Western Australia.
In clinical studies, CelGro has been shown to augment repair of severed, or damaged peripheral nerves, the rotator cuff tendon within the shoulder and guide bone regeneration within the jaw.